Lantus vs Tresiba: Cost and Access Head-to-Head

Clinical Efficacy: How A1c Lowering Compares

Both Lantus and Tresiba reduce A1c by a clinically meaningful margin, and no head-to-head trial has found a statistically significant difference in glucose-lowering potency between the two. The SWITCH trials (SWITCH 1 for type 1, SWITCH 2 for type 2 diabetes) used a treat-to-target crossover design and confirmed equivalent A1c endpoints 1.

In SWITCH 2 (N=721), patients with type 2 diabetes on insulin degludec achieved a mean A1c of 7.07% compared with 7.10% on insulin glargine U100, a difference of −0.03 percentage points (95% CI −0.12 to 0.07) 1. That gap is nowhere near clinical significance.

The distinction shows up not in A1c but in glucose variability. Tresiba's half-life exceeds 25 hours, producing a duration of action beyond 42 hours and a flatter pharmacokinetic profile 2. Lantus peaks modestly around 8 to 12 hours and requires consistent once-daily timing to avoid end-of-dose glucose rises. For patients who struggle with injection timing, this pharmacokinetic difference matters. For patients who inject at the same time every day without issue, it may not.

The American Diabetes Association's 2024 Standards of Care lists both insulin glargine and insulin degludec as first-line basal insulin options, noting that the choice between them "may be driven by cost, access, and individual patient factors" rather than efficacy 3.

Hypoglycemia Risk: Where Tresiba Pulls Ahead

Tresiba's most consistent clinical advantage is a lower rate of hypoglycemia, particularly overnight. The SWITCH 2 trial demonstrated a 53% reduction in severe or blood glucose, confirmed nocturnal hypoglycemia episodes with degludec versus glargine during the maintenance period (rate ratio 0.47, P<0.001) 1.

The DEVOTE trial (N=7,637), designed primarily to assess cardiovascular safety, confirmed this signal in a broader population. Patients randomized to degludec experienced 40% fewer severe hypoglycemic events compared with glargine (rate ratio 0.60, P<0.001 for superiority) 4. That finding held across age groups, baseline A1c levels, and renal function categories.

This is not a trivial distinction. Severe hypoglycemia carries real clinical consequences. A single severe episode in an older adult with type 2 diabetes doubles the 1-year risk of cardiovascular events, per a 2019 analysis in Diabetes Care 5. Dr. John Buse, then-president of the ADA's Medicine & Science division, stated at the 2017 ADA Scientific Sessions: "The hypoglycemia difference between degludec and glargine is clinically meaningful, particularly for patients at high risk of severe events."

For patients with hypoglycemia unawareness, recurrent nocturnal lows, or a history of severe episodes, the data favor Tresiba. For patients without these risk factors, the hypoglycemia advantage may not justify a higher out-of-pocket cost.

Cardiovascular Safety: Both Pass the Bar

Neither insulin raises red flags for cardiovascular harm. The ORIGIN trial (N=12,537) randomized patients with early dysglycemia or new type 2 diabetes to insulin glargine versus standard care and tracked MACE (major adverse cardiovascular events) over a median 6.2 years 6. Glargine was neutral on the primary composite of CV death, nonfatal MI, and nonfatal stroke (HR 1.02 to 95% CI 0.94, 1.11).

DEVOTE tested degludec against glargine directly on the same MACE composite in patients with type 2 diabetes at high CV risk (median follow-up 1.99 years). Degludec was non-inferior (HR 0.91 to 95% CI 0.78, 1.06, P<0.001 for non-inferiority) 4. These trials answer different questions. ORIGIN asked whether early insulin use harms hearts. DEVOTE asked whether switching from glargine to degludec is cardiovascularly safe. Both answers are reassuring, and neither insulin has shown a signal for CV benefit either.

The FDA granted both drugs standard labeling without cardiovascular warnings, and the 2024 ADA Standards of Care does not preferentially recommend one over the other on cardiac grounds 3.

Wholesale Acquisition Cost: The Sticker Price Gap

List prices for branded Lantus and branded Tresiba differ by roughly $140 per 5-pen carton (1,500 units). As of early 2026, branded Lantus U100 SoloStar (5 pens × 3 mL) carries a WAC near $283, while Tresiba FlexTouch U100 (5 pens × 3 mL) lists around $425 7.

That comparison changes once biosimilars enter the picture. Three FDA-approved biosimilars of insulin glargine are on the market: Semglee (Mylan/Viatris), Rezvoglar (Eli Lilly), and Hadlima's glargine entry. Semglee is available as an interchangeable biosimilar, meaning pharmacists in most states can substitute it without a new prescription. Its WAC sits near $150 for a 5-pen carton, roughly 65% below Tresiba's list price 7.

Tresiba has no biosimilar competitors. Novo Nordisk's U.S. patents on insulin degludec extend into the late 2020s, so biosimilar competition is unlikely before 2029 at the earliest. This single-source status keeps Tresiba's list price higher and gives the manufacturer less incentive to reduce WAC voluntarily.

One important caveat: WAC is not what most patients pay. Net prices after rebates can invert the WAC ranking on some formularies, because Novo Nordisk negotiates aggressively with PBMs to secure preferred status for Tresiba. The net price difference between the two drugs is smaller than the WAC gap suggests, and in some plan designs, Tresiba may actually cost the patient less at the pharmacy counter.

Insurance Formulary Placement: Plan by Plan

Formulary status is the single biggest driver of real-world out-of-pocket cost for basal insulin, and it varies enormously across plans. No universal answer exists. Here is the general pattern as of 2026.

Commercial plans managed by Express Scripts: Tresiba frequently lands on preferred brand tier (Tier 2), while branded Lantus sits on non-preferred brand tier (Tier 3). Biosimilar glargine products may land on Tier 2 or even Tier 1 depending on the employer's contract 8. CVS Caremark formularies: Both branded products typically sit on Tier 3, but Semglee (interchangeable biosimilar glargine) often receives Tier 2 placement. OptumRx: Varies by employer group, though Tresiba has been gaining preferred status since 2023.

Under Medicare Part D, the Inflation Reduction Act caps insulin copays at $35 per month per covered insulin product regardless of tier 8. Both Lantus and Tresiba are covered by nearly all Part D plans. This cap effectively neutralizes the cost difference for Medicare beneficiaries, making the clinical profile the primary decision driver rather than price.

For Medicaid, both products are generally covered, though states may require prior authorization for the higher-cost option. Check your state's preferred drug list.

The 2023 Endocrine Society Clinical Practice Guideline on type 2 diabetes pharmacotherapy notes: "Clinicians should verify formulary coverage before prescribing a specific basal insulin, as formulary status is the primary determinant of patient cost" 9.

Patient Assistance and Copay Programs

Both manufacturers run patient-facing cost-reduction programs. These programs frequently bring the copay to zero for eligible commercially insured patients, but the details and income thresholds differ.

Sanofi (Lantus): The Insulins Valogrift Patient Savings Program offers $0 copay for commercially insured patients, with a cap of $99 savings per monthly prescription. Sanofi also runs the Sanofi Patient Connection program for uninsured patients with household income below 400% of the federal poverty level, providing free Lantus for up to 12 months 10. Novo Nordisk (Tresiba): The NovoCare copay card reduces commercially insured copays to as low as $0, with maximum savings of $150 per fill. Novo Nordisk's Patient Assistance Program (PAP) supplies Tresiba free for uninsured patients earning below 400% FPL 10.

Uninsured patients paying cash should note that GoodRx and similar discount platforms frequently list biosimilar glargine (Semglee) at $80, $130 per 5-pen carton, compared to $300+ for branded Tresiba. For patients without insurance coverage, the biosimilar glargine route is typically the least expensive path to long-acting basal insulin.

Dosing Flexibility and Practical Considerations

Tresiba's ultra-long half-life permits a flexible dosing window. The FDA label allows up to an 8-hour variation in injection time from day to day without a clinically significant change in glucose control 2. Lantus requires more consistent once-daily timing. A patient who injects Lantus at 10 PM most nights but shifts to 6 AM on weekends may notice fasting glucose spikes.

This flexibility carries real value for shift workers, frequent travelers, and anyone whose schedule is unpredictable. It does not matter for patients with a fixed daily routine.

Pen device design also differs. Tresiba FlexTouch uses a push-button mechanism with no extension force needed during injection. Lantus SoloStar requires thumb pressure on the plunger throughout. Patients with limited hand strength or arthritis may find the FlexTouch easier to operate.

Both insulins are stored refrigerated before first use and at room temperature for up to 56 days (Tresiba) or 28 days (Lantus) after first use. The longer room-temperature stability of Tresiba is a minor practical advantage for patients who carry their insulin during travel.

When to Choose Lantus (or Biosimilar Glargine)

Cost-sensitive patients without frequent hypoglycemia stand to benefit most from insulin glargine. The biosimilar pathway has pushed real-world prices well below Tresiba, and for patients with stable schedules who do not experience nocturnal lows, the clinical profile is equivalent.

Specific scenarios favoring glargine:

• High out-of-pocket cost is the primary concern and the patient's plan covers biosimilar Semglee at Tier 1 or Tier 2
• The patient is newly starting basal insulin and has no history of hypoglycemia
• The patient is comfortable with consistent injection timing and does not need the flexible dosing window
• The patient is uninsured and paying cash, where biosimilar pricing is substantially lower

When to Choose Tresiba

Tresiba earns its premium when hypoglycemia risk is the clinical priority or when dosing flexibility matters for adherence.

Specific scenarios favoring degludec:

• History of severe or nocturnal hypoglycemia, where DEVOTE and SWITCH data show a 40 to 53% reduction in events
• Hypoglycemia unawareness, where even a small reduction in severe episode frequency may prevent dangerous outcomes
• Shift work or erratic schedules that make consistent once-daily injection timing impractical
• Elderly patients or those with cardiovascular disease, where severe hypoglycemia carries disproportionate risk
• Formulary placement favors Tresiba on the patient's specific plan, making the out-of-pocket cost equal to or less than glargine

The decision tree is not complicated. Check formulary placement first, then match the clinical profile to the patient's hypoglycemia risk and lifestyle.